MIM
AMRX icon

MetLife Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

MetLife Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.01M Buy
81,051
+803
+1% +$10.8K 0.01% 1389
2025
Q4 		$1.01M Sell
80,248
-8,848
-10% -$101K ﹤0.01% 1426
2025
Q3 		$892K Sell
89,096
-5,841
-6% -$52.4K ﹤0.01% 1512
2025
Q2 		$768K Hold
94,937
– – ﹤0.01% 1454
2025
Q1 		$796K Buy
94,937
+298
+0.3% +$2.49K ﹤0.01% 1475
2024
Q4 		$750K Buy
94,639
+2,297
+2% +$19.3K ﹤0.01% 1570
2024
Q3 		$768K Hold
92,342
– – ﹤0.01% 1549
2024
Q2 		$586K Buy
92,342
+35,634
+63% +$226K ﹤0.01% 1634
2024
Q1 		$344K Sell
56,708
-12,102
-18% -$68.2K ﹤0.01% 1893
2023
Q4 		$418K Hold
68,810
– – ﹤0.01% 1798
2023
Q3 		$290K Hold
68,810
– – ﹤0.01% 1981
2023
Q2 		$213K Buy
68,810
+40,998
+147% +$87.3K ﹤0.01% 2233
2023
Q1 		$38.7K Sell
27,812
-18,734
-40% -$37.3K ﹤0.01% 2732
2022
Q4 		$92.6K Sell
46,546
-9,482
-17% -$21.3K ﹤0.01% 2623
2022
Q3 		$113K Buy
56,028
+26,741
+91% +$74.9K ﹤0.01% 2624
2022
Q2 		$93.1K Sell
29,287
-29,026
-50% -$105K ﹤0.01% 2734
2022
Q1 		$243K Buy
58,313
+36,668
+169% +$162K ﹤0.01% 2237
2021
Q4 		$104K Sell
21,645
-18,760
-46% -$93.5K ﹤0.01% 2395
2021
Q3 		$216K Hold
40,405
– – ﹤0.01% 2044
2021
Q2 		$207K Hold
40,405
– – ﹤0.01% 2155
2021
Q1 		$272K Buy
40,405
+19,388
+92% +$107K ﹤0.01% 1875
2020
Q4 		$96K Sell
21,017
-13,661
-39% -$60.5K ﹤0.01% 2228
2020
Q3 		$135K Sell
34,678
-20,595
-37% -$88.1K ﹤0.01% 2077
2020
Q2 		$263K Hold
55,273
– – ﹤0.01% 1737
2020
Q1 		$192K Hold
55,273
– – ﹤0.01% 1720
2019
Q4 		$266K Buy
55,273
+14,736
+36% +$51.2K ﹤0.01% 1821
2019
Q3 		$118K Hold
40,537
– – ﹤0.01% 2240
2019
Q2 		$291K Hold
40,537
– – ﹤0.01% 1804
2019
Q1 		$574K Hold
40,537
– – 0.01% 1370
2018
Q4 		$548K Hold
40,537
– – 0.01% 1311
2018
Q3 		$900K Buy
+40,537
New +$853K 0.01% 1184

Other funds holding AMRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

MetLife Investment Management's AMRX Position: Q1 2026 in Review

MetLife Investment Management increased its Amneal Pharmaceuticals (AMRX) stake by 1% in Q1 2026, buying an estimated $10.8K and bringing the position to 81,051 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1389.

MetLife Investment Management first reported a position in AMRX in Q3 2018 and has held it in 31 quarters since. The position peaked at $1.01M in Q4 2025. 315 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • MetLife Investment Management held 81,051 shares of Amneal Pharmaceuticals worth $1.01M as of Q1 2026.
  • MetLife Investment Management bought 803 Amneal Pharmaceuticals shares in Q1 2026, an estimated $10.8K.
  • Amneal Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #1389 holding.
  • MetLife Investment Management first reported a position in Amneal Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • MetLife Investment Management's Amneal Pharmaceuticals position peaked at $1.01M in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.